Apixio Series C preferred stock growth investment by Bain Capital
$13,500,000
First Analysis acted as the exclusive placement agent in a $13.5 million growth capital raise, closed in April 2014, for Apixio Inc. – a leading provider of big data solutions for healthcare analytics. First Analysis provided advisory expertise to Apixio throughout the transaction, including preparation, positioning, investor coordination and contact, due diligence and negotiation.
About Apixio:
Headquartered in San Mateo, Calif. and powered by its cognitive computing platform, Apixio brings advanced data to healthcare by extracting and analyzing previously trapped unstructured medical record data, giving healthcare payers and providers unprecedented access to groundbreaking insights. The Company’s computing platform is built upon the insights from analyzing more than six million patient charts. Apixio’s HCC Profiler Solution mines medical charts and Medicare-reported chronic condition data to help its customers compute patient risk scores more efficiently and accurately than they could with traditional chart review methods. It also enables more targeted care delivery and helps Medicare set payor and provider payment for patients enrolled in Medicare Advantage (MA), powering more cost-effective, high-quality care.
About Bain Capital Ventures:
Bain Capital Ventures partners with disruptive founders to accelerate their ideas to market. The firm invests from seed to growth in enterprise software, infrastructure software, and industries being transformed by data. Bain Capital Ventures has helped launch and commercialize 200-plus companies since 2000, including investments in DocuSign, Jet.com, Kiva Systems, LinkedIn, Rapid7, SurveyMonkey, Taleo, and TellApart. Bain Capital Ventures has approximately $3.6 billion of assets under management with offices in San Francisco, New York, and Boston.